These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33888356)

  • 1. Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer.
    Berchuck JE; Zhang Z; Silver R; Kwak L; Xie W; Lee GM; Freedman ML; Kibel AS; Van Allen EM; McKay RR; Taplin ME
    Eur Urol; 2021 Sep; 80(3):295-303. PubMed ID: 33888356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade.
    McKay RR; Montgomery B; Xie W; Zhang Z; Bubley GJ; Lin DW; Preston MA; Trinh QD; Chang P; Wagner AA; Mostaghel EA; Kantoff PW; Nelson PS; Kibel AS; Taplin ME
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):364-372. PubMed ID: 29263420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.
    Taplin ME; Montgomery B; Logothetis CJ; Bubley GJ; Richie JP; Dalkin BL; Sanda MG; Davis JW; Loda M; True LD; Troncoso P; Ye H; Lis RT; Marck BT; Matsumoto AM; Balk SP; Mostaghel EA; Penning TM; Nelson PS; Xie W; Jiang Z; Haqq CM; Tamae D; Tran N; Peng W; Kheoh T; Molina A; Kantoff PW
    J Clin Oncol; 2014 Nov; 32(33):3705-15. PubMed ID: 25311217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.
    Heidenreich A; Fossati N; Pfister D; Suardi N; Montorsi F; Shariat S; Grubmüller B; Gandaglia G; Briganti A; Karnes RJ
    Eur Urol Oncol; 2018 May; 1(1):46-53. PubMed ID: 31100228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status.
    McClintock TR; von Landenberg N; Cole AP; Lipsitz SR; Gild P; Sun M; Fletcher SA; Roghmann F; Menon M; Nguyen PL; Noldus J; Choueiri TK; Kibel AS; Trinh QD
    Ann Surg Oncol; 2019 Jan; 26(1):297-305. PubMed ID: 30430324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of Post-Neoadjuvant Intense Hormone Therapy and Surgery for High Risk Localized Prostate Cancer: Results of a Pooled Analysis of Contemporary Clinical Trials.
    McKay RR; Berchuck J; Kwak L; Xie W; Silver R; Bubley GJ; Chang PK; Wagner A; Zhang Z; Kibel AS; Taplin ME
    J Urol; 2021 Jun; 205(6):1689-1697. PubMed ID: 33502237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues.
    Chang SS; Reuter VE; Heston WD; Hutchinson B; Grauer LS; Gaudin PB
    Cancer; 2000 Jan; 88(2):407-15. PubMed ID: 10640975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
    Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
    Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study.
    Casadei C; Scarpi E; Conteduca V; Gurioli G; Cursano MC; Brighi N; Lolli C; Schepisi G; Basso U; Fornarini G; Bleve S; Farolfi A; Altavilla A; Burgio SL; Giunta EF; Gianni C; Filograna A; Ulivi P; Olmos D; Castro E; De Giorgi U
    Eur Urol Open Sci; 2024 Mar; 61():44-51. PubMed ID: 38384439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer.
    Wu Y; Yu H; Li S; Wiley K; Zheng SL; LaDuca H; Gielzak M; Na R; Sarver BAJ; Helfand BT; Walsh PC; Lotan TL; Cooney KA; Black MH; Xu J; Isaacs WB
    Eur Urol Oncol; 2020 Apr; 3(2):224-230. PubMed ID: 31948886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer.
    Meyer F; Bairati I; Bédard C; Lacombe L; Têtu B; Fradet Y
    Urology; 2001 Aug; 58(2 Suppl 1):71-7. PubMed ID: 11502453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
    Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
    Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Avoiding androgen deprivation therapy in men with high-risk prostate cancer: the role of radical prostatectomy as initial treatment.
    Miocinovic R; Berglund RK; Stephenson AJ; Jones JS; Fergany A; Kaouk J; Klein EA
    Urology; 2011 Apr; 77(4):946-50. PubMed ID: 21477723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular and Thromboembolic Events in Patients With Localized Prostate Cancer Receiving Intensified Neoadjuvant Androgen Deprivation: A Systematic Review and Meta-Analysis.
    Felício de Campos E; Xavier CB; Queiroz MM; Firmino Lima Júnior N; Ilario EN; Coelho RF; Nahas WC; Bastos DA; Fontes Jardim DL
    Clin Genitourin Cancer; 2024 Jun; 22(3):102088. PubMed ID: 38718699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Androgen Deprivation Therapy and Patient-reported Depression in Men With Recurrent Prostate Cancer.
    Thomas HR; Chen MH; D'Amico AV; Bennett CL; Kattan MW; Sartor O; Stein K; Nguyen PL
    Clin Genitourin Cancer; 2018 Aug; 16(4):313-317. PubMed ID: 29866496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy.
    Wilkinson S; Ye H; Karzai F; Harmon SA; Terrigino NT; VanderWeele DJ; Bright JR; Atway R; Trostel SY; Carrabba NV; Whitlock NC; Walker SM; Lis RT; Abdul Sater H; Capaldo BJ; Madan RA; Gulley JL; Chun G; Merino MJ; Pinto PA; Salles DC; Kaur HB; Lotan TL; Venzon DJ; Choyke PL; Turkbey B; Dahut WL; Sowalsky AG
    Eur Urol; 2021 Dec; 80(6):746-757. PubMed ID: 33785256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought.
    Bravi CA; Fossati N; Gandaglia G; Suardi N; Mazzone E; Robesti D; Osmonov D; Juenemann KP; Boeri L; Jeffrey Karnes R; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A
    Eur Urol; 2020 Nov; 78(5):661-669. PubMed ID: 32624288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgery with or Without Darolutamide in High-risk and/or Locally Advanced Prostate Cancer: The SUGAR (CCAFU-PR2) Phase 2 Trial Rationale and Protocol.
    Calleris G; Filleron T; Kesch C; Roubaud G; Pradère B; Cabarrou B; Malavaud B; Roupret M; Mourey L; Ploussard G
    Eur Urol Oncol; 2024 Jun; 7(3):494-500. PubMed ID: 37806843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.